DE69519802D1 - Etherlipid-liposomen und deren therapeutische verwendung - Google Patents

Etherlipid-liposomen und deren therapeutische verwendung

Info

Publication number
DE69519802D1
DE69519802D1 DE69519802T DE69519802T DE69519802D1 DE 69519802 D1 DE69519802 D1 DE 69519802D1 DE 69519802 T DE69519802 T DE 69519802T DE 69519802 T DE69519802 T DE 69519802T DE 69519802 D1 DE69519802 D1 DE 69519802D1
Authority
DE
Germany
Prior art keywords
liposomes
etherlipid
therapeutic use
phosphatidylethanolamine
underivatized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69519802T
Other languages
English (en)
Other versions
DE69519802T2 (de
Inventor
Eric Mayhew
S Janoff
Imran Ahmad
K Bhatia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of DE69519802D1 publication Critical patent/DE69519802D1/de
Application granted granted Critical
Publication of DE69519802T2 publication Critical patent/DE69519802T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]
DE69519802T 1994-10-14 1995-10-12 Etherlipid-liposomen und deren therapeutische verwendung Expired - Fee Related DE69519802T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32304294A 1994-10-14 1994-10-14
PCT/US1995/012721 WO1996011670A1 (en) 1994-10-14 1995-10-12 Ether lipid liposomes and their therapeutic use

Publications (2)

Publication Number Publication Date
DE69519802D1 true DE69519802D1 (de) 2001-02-08
DE69519802T2 DE69519802T2 (de) 2001-04-19

Family

ID=23257529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69519802T Expired - Fee Related DE69519802T2 (de) 1994-10-14 1995-10-12 Etherlipid-liposomen und deren therapeutische verwendung

Country Status (15)

Country Link
US (1) US5762958A (de)
EP (1) EP0785773B1 (de)
JP (1) JPH10507450A (de)
KR (1) KR100381449B1 (de)
AT (1) ATE198419T1 (de)
AU (1) AU707414B2 (de)
CA (1) CA2199179A1 (de)
DE (1) DE69519802T2 (de)
DK (1) DK0785773T3 (de)
ES (1) ES2153053T3 (de)
FI (1) FI971494A0 (de)
GR (1) GR3035689T3 (de)
NO (1) NO316206B1 (de)
PT (1) PT785773E (de)
WO (1) WO1996011670A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667053B1 (en) 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
USRE39042E1 (en) * 1996-02-16 2006-03-28 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US5965159A (en) * 1996-02-16 1999-10-12 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5932242A (en) * 1996-10-15 1999-08-03 The Liposome Company, Inc. Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof
DE19829448A1 (de) * 1998-07-01 2000-10-12 Medmark Pharma Gmbh 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
ES2154560B1 (es) * 1998-09-16 2001-12-01 Lipotec Sa Composicion a base de derivados de cromanos y su uso para reducir quimicamente las reacciones oxidativas o inducidas por radicales libres.
WO2000037088A1 (en) * 1998-12-21 2000-06-29 Inkeysa.Sa Use of etherlysophospholipids as antiinflammatory agents
US8916539B2 (en) 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US9040078B2 (en) 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
US7893226B2 (en) 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US8501701B2 (en) 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US7608598B2 (en) 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US8076312B2 (en) 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US7772196B2 (en) 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US8304395B2 (en) 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
US8883761B2 (en) 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
ATE491437T1 (de) * 2004-10-19 2011-01-15 Mpg Max Planck Ges Zur Foerderung Der Wissenschaften E V Formulierungen mit alkylphosphocholinen unter verwendung von neuen negativen ladungsträgern
EA012138B1 (ru) * 2004-11-17 2009-08-28 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим Применение конъюгатов липидов при лечении заболеваний
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
DE102006019907A1 (de) * 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung
CA2705785A1 (en) 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
ES2391226T3 (es) * 2006-12-20 2012-11-22 Alphaptose Gmbh Forma farmacéutica tópica que comprende compuestos de glicerol tri-sustituido
US9161944B2 (en) 2010-02-18 2015-10-20 Inserm (Institut National De La Sante Et De La Sante Et De La Recherche Medicale) Method for preventing cancer metastasis
US20150132369A1 (en) * 2013-11-09 2015-05-14 Exir Nano Sina Company Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
US4163748A (en) * 1973-09-06 1979-08-07 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Propane-1,3-diol phosphatides and method of preparing the same
US4159988A (en) * 1974-08-06 1979-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic phospholipids, a process for their manufacture and their use
DE2619686C2 (de) * 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
DE3011738A1 (de) * 1980-03-26 1981-10-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue glycerin-3-phosphorsaeurehalogenalkylester
DE3239858A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden
JPS5972294A (ja) * 1982-10-18 1984-04-24 Hisaji Nakamura スピ−カ装置
US4983397A (en) * 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4965391A (en) * 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
DE4132345A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Ether-lysolecithine und alkylphosphocholine in liposomen
AU2776692A (en) * 1991-10-23 1993-05-21 National Research Council Of Canada Formation of stable liposomes from lipid extracts of archaeobacteria (archaea)
EP1118326A3 (de) * 1993-05-21 2002-07-31 The Liposome Company, Inc. Reduzierung von durch Liposomen induzierten physiologischen Gegenreaktionen
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie

Also Published As

Publication number Publication date
FI971494A (fi) 1997-04-10
NO971643L (no) 1997-06-09
JPH10507450A (ja) 1998-07-21
ATE198419T1 (de) 2001-01-15
AU3762595A (en) 1996-05-06
WO1996011670A1 (en) 1996-04-25
FI971494A0 (fi) 1997-04-10
NO316206B1 (no) 2003-12-29
ES2153053T3 (es) 2001-02-16
PT785773E (pt) 2001-05-31
EP0785773A1 (de) 1997-07-30
GR3035689T3 (en) 2001-07-31
AU707414B2 (en) 1999-07-08
NO971643D0 (no) 1997-04-10
KR100381449B1 (ko) 2003-07-18
KR970705378A (ko) 1997-10-09
EP0785773B1 (de) 2001-01-03
DE69519802T2 (de) 2001-04-19
CA2199179A1 (en) 1996-04-25
DK0785773T3 (da) 2001-01-29
US5762958A (en) 1998-06-09

Similar Documents

Publication Publication Date Title
DE69519802D1 (de) Etherlipid-liposomen und deren therapeutische verwendung
ES2186792T3 (es) Metodos de fabricar liposomas que contienen fotosensibilizantes hidro-monobenzoporfirinicos.
DE69324367D1 (de) Kationische lipide
DE69508598D1 (de) Mit polyethylenglycol modifizierte ceramidlipide und liposomen
ES2194114T3 (es) Formulaciones liposomicas de mitoxantrona.
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
FI843930A0 (fi) Maerkta konjugat av metalltionein och maolsoekande biologiskt aktiva molekyler.
TR200100868T2 (tr) Indeno-,nafto-, benzosiklohepta-dihidrotiyazol türevleri, imalatları, anorektal ilaç olarak kullanılmaları.
FI965144A0 (fi) Sterolijohdannaiset käytettäviksi meioosin säätelyyn
TR199700872A3 (tr) Kompleks lipid' lerin kullanilmasi.
IT1285770B1 (it) Composti corticoidei
ATE226843T1 (de) Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
ES2192610T3 (es) Aminouracilos substituidos.
ES2164765T3 (es) Heterociclilbenzonitrilos.
NZ335125A (en) Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof
ES538982A0 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
ES2069990T3 (es) Acido acilaminoalquilidenhidroxibisfosfonico util en la terapia de enfermedades osteoarticulares.
DE9405350U1 (de) Therapietisch für Rollstühle
IT1251840B (it) Uso di formulazioni liposomiali contenenti papaverina nel trattamento della impotenza maschile
DE3373907D1 (en) N-acyl derivatives of dipeptides, their manufacture and use in treating diseases, and means therefor
IT9011726U1 (it) Magneto terapia in casa e in auto. il trovato consiste nell'utilizzare questo apparecchio terapeutico in casa ed in auto senza l'ausilio di alcuna pila ma sfruttando un trasformatore esterno in casa e la presa accendisigari in auto, il tutto ha un as
ITMI950729A1 (it) Uso della lisofosfatidilcolina nel campo della riproduzione umana
AU3634795A (en) Clotrimazole metabolites in the treatment of sickle cell disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee